Chris Nasveschuk Senior Vice President, Chemistry
C4 Therapeutics Inc.
“Aragen’s expertise across chemistry and biology has helped C4T further research in targeted protein degradation. With close collaboration and trust between our teams, we enjoy working with Aragen to further our shared commitment to advancing scientific research to develop innovative medicines for patients.”
Dr. Kathleen Shelton Vice President and Chief Technology Officer
FMC Corporation
“Aragen has been a valued collaborator of FMC for several years. This partnership extends across multiple disciplines in research and development and we appreciate our strong working relationship.”
Rajat Sood Managing Director
Goldman Sachs Asset Management
“Aragen is well positioned to benefit from the secular trend of increased outsourcing by the life sciences industry. With a clear value creation plan in place, we look forward to closely working with the management and shareholders of Aragen. Goldman Sachs is actively seeking to invest and foster leading, national champions of India who are building companies of a global scale.”
Alan Joslyn, Ph.D. President and CEO
Oragenics Inc.
“Developing a variety of vaccine alternatives is critical to bringing the SARS-Cov-2 pandemic under control. Utilizing the technology created at NIH with Aragen’s pre-clinical development capabilities will help us accelerate the development of the TerraCov2 vaccine candidate. We believe the relationship between the companies will result in advancement of the vaccine candidate into the clinic as rapidly as possible,”
Timothy Compton Chief Commercial Officer
Avid Bioservices
“With pharmaceutical and biotechnology companies focused on delivering their innovative medicines to patients as quickly as possible, this alliance aims to speed the entire cGMP manufacturing process by having a single, integrated team oversee a single, integrated project timeline with significant built-in process efficiencies. We view this collaboration with Aragen as a significant win for current and future clients of both companies and we are excited to contribute our deep CDMO expertise to the partnership, particularly our more than 15 years of commercial product manufacturing experience.”
Dr Andrew Growth Faculty of Science, University of Technology Sydney (UTS)
“UTS welcomes the strategic partnership with Aragen to provide comprehensive but affordable cell line and expression technology solutions to Australian research communities and start-ups, to tackle the critical bottleneck during pre- and early-clinical stages of biologics development.”
Adar Poonawalla Chief Executive Officer
Serum Institute of India Pvt. Ltd. (SIIPL)
“SIIPL is very pleased to join hands with Aragen. SIIPL is already in collaboration with IAVI and Scripps Research for the discovery of novel monoclonal antibodies against HIV. With our manufacturing capabilities and this collaboration with Aragen to develop stable cell lines, SIIPL will be able to provide cost-effective monoclonal antibodies against HIV for the developing and developed world.”